ALG-055009 vs Resmetirom
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: Thyroid hormone receptor-beta · full MASH / NASH pipeline
ALG-055009
Developed by Aligos Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Resmetirom · Rezdiffra
Marketed by Madrigal Pharmaceuticals
NCT03900429 · Phase 3 · active, not recruiting
MAESTRO-NASH was a randomized, double-blind, placebo-controlled Phase 3; the month-12 analysis included 888 patients with F2-F3 fibrosis. Both doses met both liver-biopsy endpoints. Biopsy histology is a surrogate that supported accelerated approval, not a clinical outcome, so the grade is moderate.
Next expected readout: December 2026 · NCT05500222 (registry estimate)
Reported efficacy
Week 52 Dual Primary Objectives: To determine the effect of 80 or 100 mg MGL-3196 vs matching placebo on liver biopsy (NASH CRN score) at Week 52 compared with Baseline (52 weeks); Month 54 Primary Objective: Time to experiencing an adjudicated Composite Clinical Outcome event (Final Primary Endpoint, at 54 months) (up to 54 months): Month-12 histology (n=888): MASH resolution without fibrosis worsening 26-27% (80 mg) and 24-36% (100 mg) vs 9-13% placebo; fibrosis improvement without MASH worsening 23% (80 mg) and 24-28% (100 mg) vs 13-15% placebo (ranges across the two pathologists); both endpoints statistically significant for both doses (REZDIFFRA label, Trial 1). (met)
Result source: NCT03900429
Results for MASH / NASH
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALG-055009 | Resmetirom |
|---|---|---|
| MASH resolution without fibrosis worsening | —Not reported | 27.4% vs 14.7%+12.7 vs placeboNCT02912260 |
| Fibrosis stage, change | —Not reported | —Not posted · NCT04197479 |
| Liver fat (MRI-PDFF), change | —Not reported | -8.2% vs -2.9%−5.3 vs placeboNCT029122601 other result
|
| ALT, change | —Not reported | -15.4 vs 11−26.4 vs placeboNCT029122601 other result
|
MASH resolution without fibrosis worsening
- ALG-055009
- —Not reported
- Resmetirom
- 27.4% vs 14.7%+12.7 vs placeboNCT02912260
Fibrosis stage, change
- ALG-055009
- —Not reported
- Resmetirom
- —Not posted · NCT04197479
Liver fat (MRI-PDFF), change
- ALG-055009
- —Not reported
- Resmetirom
- -8.2% vs -2.9%−5.3 vs placeboNCT02912260
1 other result
- -7% vs -2.7% NCT02912260
ALT, change
- ALG-055009
- —Not reported
- Resmetirom
- -15.4 vs 11−26.4 vs placeboNCT02912260
1 other result
- -8.2 vs -5.2 NCT02912260
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALG-055009: no structured comparison results are available for MASH / NASH.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ALG-055009: 0 of 4 rows · Resmetirom: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Resmetirom |
|---|---|
| Dropout rate | —Extension Studya NCT02912260 · Phase 2 · registry result, not featured evidence show 2 more results11.9%MGL-3196 NCT02912260 · Phase 2 · registry result, not featured evidence —MGL-3196 Main Study NCT02912260 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —Extension Studya NCT02912260 · Phase 2 · registry result, not featured evidence show 2 more results3.6%MGL-3196 NCT02912260 · Phase 2 · registry result, not featured evidence —MGL-3196 Main Study NCT02912260 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%Extension Studya NCT02912260 · Phase 2 · registry result, not featured evidence show 2 more results—MGL-3196 NCT02912260 · Phase 2 · registry result, not featured evidence 6%MGL-3196 Main Study NCT02912260 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 9.7% (placebo 4.9%) abdominal discomfort 6.5% (placebo 0%) constipation 6.5% (placebo 0%) NCT02912260 · Phase 2 · registry result, not featured evidence show 1 more resultdiarrhoea 36.9% (placebo 9.8%) nausea 20.2% (placebo 4.9%) headache 13.1% (placebo 14.6%) NCT02912260 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Resmetirom
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 3 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALG-055009's landscape · Resmetirom's landscape